von Moos R, et al. - In view of the observation that multitarget tyrosine kinase inhibitor sorafenib has radiosensitising effects, researchers performed phase I/II study of capecitabine + sorafenib + RT in KRAS-mutant locally advanced rectal cancers (LARCs) to establish the maximum tolerated dose of the regimen (in phase I) and to determine the pathologic complete response rate (in phase II) defined as Dworak regression grade 3 and 4. In patients with KRAS-mutated LARC, combining sorafenib and standard chemoradiotherapy with capecitabine was highly active with acceptable toxicity and justified further investigation.